Efficacy and Safety of Various Graft Choices in OLIF

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20260502003

Enrollment

Registered

2026-05-02

Start date

2026-03-31

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Degenerative lumbar disease Degenerative lumbar disease Oblique Lumbar Interbody Fusion Demineralized bone matrix Recombinant human bone morphogenetic protein-2

Interventions

OLIF with Demineralized Bone Matrix ,OLIF with Chinese hamster ovarian(CHO) cell derived rhBMP-2,OLIF with E. coli derived rhBMP-2

Treatment,Treatment,Treatment

Demineralized Bone Matrix ,Chinese hamster ovarian(CHO) cell derived rhBMP-2,E. coli derived rhBMP-2

Eligibility

Sex/Gender

All

Age

40 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Degenerative lumbar disease level between L2-L5 who underwent Oblique Lumbar Interbody Fusion (OLIF) 2. at least 12 months of follow-up with complete clinical and radiologic data

Exclusion criteria

Exclusion criteria: 1.previous lumbar spine surgery 2.infection, trauma or tumors at the lumbar spine 3.incomplete follow-up data

Design outcomes

Primary

Measure	Time frame
Fusion status 12 month Computed Tomography(CT) spine	—

Secondary

Measure	Time frame
Subsidence 12 month Computed Tomography(CT) spine, Leg and back pain 1, 3, 6, 12 month after surgery Visual analogue scale,Oswestry Disability Index (ODI) 1, 3, 6, 12 month after surgery Oswestry LBP Disability Questionnaire Thai version,EQ-5D-5L 1, 3, 6, 12 month after surgery EQ-5D-5L Questionnaire Thai version	—

Countries

Thailand

Contacts

Public ContactWantanun Lorwatthanakitchai

Faculty of Medicine, Chulalongkorn University

wantanun.pla@gmail.com026494000

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026